Klotho Neurosciences, Inc.

NASDAQ KLTO
$0.49 -0.0100 -2.00%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 15 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
6.50M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
5.93M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
28.51M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
0.02 %

Upcoming events Klotho Neurosciences, Inc.

All events
No upcoming events scheduled

Stock chart Klotho Neurosciences, Inc.

Stock analysis Klotho Neurosciences, Inc.

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.84 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
7.88 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.87 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.08 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-1207.48 -50.00

Price change Klotho Neurosciences, Inc. per year

0.13$ 2.01$
Min Max

Summary analysis Klotho Neurosciences, Inc.

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Klotho Neurosciences, Inc.

Revenue and net income Klotho Neurosciences, Inc.

All parameters

About company Klotho Neurosciences, Inc.

Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.
Address:
13576 Walnut Street, Omaha, NE, United States, 68144
Company name: Klotho Neurosciences, Inc.
Issuer ticker: KLTO
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2024-09-17
Sector: Healthcare
Industry: Biotechnology
Site: https://klothoneuro.com